biperiden ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
374 514-65-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • biperiden
  • akineton
  • biperiden hydrochloride
  • biperiden lactate
  • biperiden HCl
A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
  • Molecular weight: 311.47
  • Formula: C21H29NO
  • CLOGP: 4.94
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 23.47
  • ALOGS: -4.86
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O
10 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.64 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.10 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 24 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 8, 1959 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 259.73 31.68 79 4963 11051 50589031
Drug interaction 150.61 31.68 138 4904 199483 50400599
Suicide attempt 136.88 31.68 77 4965 51655 50548427
Hyperprolactinaemia 118.89 31.68 33 5009 3332 50596750
Extrapyramidal disorder 106.06 31.68 41 5001 11729 50588353
Psychotic symptom 103.19 31.68 24 5018 1188 50598894
Sopor 97.71 31.68 45 4997 19834 50580248
Salivary hypersecretion 93.12 31.68 32 5010 6559 50593523
Restlessness 90.52 31.68 46 4996 25127 50574955
Dyskinesia 88.94 31.68 47 4995 27814 50572268
Drug abuse 87.11 31.68 61 4981 59785 50540297
Delusion 81.83 31.68 33 5009 10536 50589546
Oromandibular dystonia 78.47 31.68 16 5026 424 50599658
Logorrhoea 69.44 31.68 20 5022 2304 50597778
Schizophrenia 67.45 31.68 26 5016 7371 50592711
Inappropriate affect 63.53 31.68 15 5027 792 50599290
Intentional self-injury 62.65 31.68 35 5007 23077 50577005
Dysarthria 61.19 31.68 41 5001 37362 50562720
Tremor 59.61 31.68 65 4977 114838 50485244
Somnolence 59.33 31.68 75 4967 154910 50445172
Hallucination, auditory 54.93 31.68 25 5017 10703 50589379
Altered state of consciousness 53.52 31.68 31 5011 21879 50578203
Blood creatine phosphokinase increased 53.23 31.68 33 5009 26334 50573748
Sluggishness 53.03 31.68 19 5023 4394 50595688
Intentional overdose 52.37 31.68 46 4996 62458 50537624
Agitation 52.33 31.68 43 4999 53341 50546741
Persecutory delusion 51.60 31.68 16 5026 2371 50597711
Negative symptoms in schizophrenia 51.33 31.68 9 5033 102 50599980
Akathisia 51.24 31.68 22 5020 8207 50591875
Muscle rigidity 50.63 31.68 23 5019 9806 50590276
Psychomotor hyperactivity 48.65 31.68 22 5020 9279 50590803
Confabulation 48.30 31.68 10 5032 286 50599796
Dystonia 46.39 31.68 23 5019 11903 50588179
Rhabdomyolysis 45.89 31.68 35 5007 38992 50561090
Galactorrhoea 44.62 31.68 16 5026 3707 50596375
Urinary incontinence 43.92 31.68 30 5012 28178 50571904
Parkinsonism 43.36 31.68 20 5022 8827 50591255
Rabbit syndrome 41.83 31.68 9 5033 311 50599771
Hyperammonaemic encephalopathy 41.54 31.68 13 5029 1986 50598096
Stupor 41.45 31.68 15 5027 3568 50596514
Catatonia 40.84 31.68 15 5027 3721 50596361
Eosinophilic myocarditis 40.65 31.68 9 5033 356 50599726
Reduced facial expression 40.07 31.68 12 5030 1582 50598500
Blood prolactin increased 39.73 31.68 14 5028 3085 50596997
Cogwheel rigidity 38.79 31.68 12 5030 1765 50598317
Drug monitoring procedure incorrectly performed 36.70 31.68 7 5035 130 50599952
Bradykinesia 36.44 31.68 14 5028 3929 50596153
Serotonin syndrome 35.46 31.68 25 5017 24688 50575394
Accommodation disorder 35.19 31.68 8 5034 357 50599725
Resting tremor 34.49 31.68 9 5033 717 50599365
Distractibility 34.32 31.68 8 5034 399 50599683
Parkinsonian gait 33.67 31.68 8 5034 434 50599648
Mental impairment 31.97 31.68 18 5024 12026 50588056
Disorganised speech 31.72 31.68 9 5033 982 50599100

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 239.67 26.51 97 5654 16051 29552725
Colitis ischaemic 171.71 26.51 58 5693 5765 29563011
Intentional self-injury 119.39 26.51 55 5696 12406 29556370
Schizophrenia 109.66 26.51 43 5708 6522 29562254
Delusion 102.75 26.51 48 5703 11168 29557608
Salivary hypersecretion 101.23 26.51 42 5709 7367 29561409
Sopor 88.57 26.51 43 5708 10891 29557885
Psychotic disorder 78.42 26.51 49 5702 20305 29548471
Extrapyramidal disorder 77.05 26.51 39 5712 10792 29557984
Altered state of consciousness 67.00 26.51 44 5707 19845 29548931
Blood creatine phosphokinase increased 65.72 26.51 58 5693 40586 29528190
Oropharyngeal spasm 65.34 26.51 13 5738 149 29568627
Dyskinesia 64.23 26.51 43 5708 20018 29548758
Restlessness 62.71 26.51 44 5707 22101 29546675
Psychiatric symptom 60.81 26.51 23 5728 3161 29565615
Self-injurious ideation 60.05 26.51 19 5732 1532 29567244
Sedation 59.83 26.51 39 5712 17366 29551410
Aggression 58.01 26.51 51 5700 35490 29533286
Akathisia 56.04 26.51 27 5724 6715 29562061
Pneumonia aspiration 54.59 26.51 50 5701 36687 29532089
Delirium 53.50 26.51 51 5700 39346 29529430
Persecutory delusion 50.24 26.51 18 5733 2123 29566653
Rhabdomyolysis 49.48 26.51 60 5691 60748 29508028
Stupor 49.44 26.51 19 5732 2725 29566051
Suicide attempt 47.92 26.51 45 5706 34065 29534711
Hallucination, auditory 47.07 26.51 27 5724 9566 29559210
Depressed level of consciousness 46.73 26.51 46 5705 36896 29531880
Patient restraint 46.72 26.51 9 5742 86 29568690
Dysphagia 45.99 26.51 55 5696 54871 29513905
Muscle rigidity 44.88 26.51 26 5725 9385 29559391
Ileus paralytic 43.66 26.51 21 5730 5202 29563574
Post-injection delirium sedation syndrome 42.27 26.51 11 5740 439 29568337
Drug interaction 40.46 26.51 106 5645 197279 29371497
Postoperative respiratory failure 39.87 26.51 8 5743 96 29568680
Parkinsonism 39.81 26.51 22 5729 7256 29561520
Psychomotor retardation 37.71 26.51 16 5735 2960 29565816
Megacolon 35.81 26.51 13 5738 1592 29567184
Psychomotor hyperactivity 34.73 26.51 21 5730 8192 29560584
Intentional overdose 34.59 26.51 40 5711 38488 29530288
Overdose 34.14 26.51 58 5693 79761 29489015
Psychotic symptom 33.60 26.51 12 5739 1402 29567374
Shock 33.48 26.51 30 5721 21374 29547402
Polydipsia 32.24 26.51 15 5736 3450 29565326
Tardive dyskinesia 31.83 26.51 17 5734 5241 29563535
Agitation 31.37 26.51 44 5707 51260 29517516
Tension 30.07 26.51 12 5739 1901 29566875
Drug screen false positive 29.12 26.51 9 5742 671 29568105
Sudden death 28.68 26.51 23 5728 14087 29554689
Social avoidant behaviour 28.19 26.51 13 5738 2929 29565847

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 467.28 24.26 170 10495 24826 64463241
Delusion 196.45 24.26 83 10582 17931 64470136
Salivary hypersecretion 180.99 24.26 70 10595 12043 64476024
Schizophrenia 175.66 24.26 67 10598 11101 64476966
Sopor 171.30 24.26 88 10577 29573 64458494
Extrapyramidal disorder 167.44 24.26 76 10589 19476 64468591
Intentional self-injury 167.24 24.26 86 10579 28958 64459109
Colitis ischaemic 150.22 24.26 63 10602 13351 64474716
Drug interaction 146.28 24.26 234 10431 361849 64126218
Restlessness 144.53 24.26 87 10578 39698 64448369
Suicide attempt 141.61 24.26 107 10558 70900 64417167
Dyskinesia 137.59 24.26 84 10581 39304 64448763
Psychotic symptom 126.24 24.26 35 10630 2103 64485964
Altered state of consciousness 120.15 24.26 76 10589 37826 64450241
Blood creatine phosphokinase increased 118.41 24.26 89 10576 58469 64429598
Hyperprolactinaemia 112.04 24.26 37 10628 4028 64484039
Persecutory delusion 99.37 24.26 34 10631 4124 64483943
Hallucination, auditory 97.01 24.26 50 10615 16889 64471178
Akathisia 96.18 24.26 44 10621 11466 64476601
Rhabdomyolysis 94.77 24.26 95 10570 91631 64396436
Muscle rigidity 89.88 24.26 48 10617 17425 64470642
Psychotic disorder 89.27 24.26 61 10604 34517 64453550
Stupor 87.02 24.26 34 10631 6001 64482066
Agitation 86.68 24.26 89 10576 88278 64399789
Aggression 86.25 24.26 67 10598 46165 64441902
Pneumonia aspiration 85.59 24.26 74 10591 59197 64428870
Psychomotor hyperactivity 80.86 24.26 42 10623 14409 64473658
Delirium 79.54 24.26 76 10589 69118 64418949
Parkinsonism 78.21 24.26 41 10624 14332 64473735
Psychiatric symptom 75.40 24.26 31 10634 6242 64481825
Ileus paralytic 72.92 24.26 33 10632 8382 64479685
Tremor 69.67 24.26 103 10562 148127 64339940
Drug abuse 68.07 24.26 96 10569 132278 64355789
Psychomotor retardation 67.25 24.26 27 10638 5116 64482951
Somnolence 63.98 24.26 118 10547 203527 64284540
Oromandibular dystonia 63.47 24.26 17 10648 896 64487171
Oropharyngeal spasm 61.20 24.26 13 10652 249 64487818
Self-injurious ideation 60.58 24.26 22 10643 3175 64484892
Sedation 58.29 24.26 51 10614 41411 64446656
Dystonia 57.69 24.26 37 10628 18828 64469239
Logorrhoea 55.47 24.26 22 10643 4037 64484030
Dysarthria 54.92 24.26 58 10607 59348 64428719
Inappropriate affect 53.33 24.26 16 10649 1272 64486795
Catatonia 50.98 24.26 25 10640 7595 64480472
Fatigue 50.29 24.26 31 10634 748699 63739368
Megacolon 50.28 24.26 19 10646 3063 64485004
Arthralgia 49.91 24.26 7 10658 442253 64045814
Depressed level of consciousness 49.35 24.26 64 10601 81372 64406695
Intentional overdose 48.85 24.26 67 10598 89877 64398190
Treatment noncompliance 48.51 24.26 47 10618 43435 64444632
Patient restraint 47.28 24.26 9 10656 96 64487971
Post-injection delirium sedation syndrome 47.17 24.26 12 10653 516 64487551
Dysphagia 46.98 24.26 72 10593 106740 64381327
Social avoidant behaviour 46.35 24.26 20 10645 4537 64483530
Headache 46.34 24.26 15 10650 529452 63958615
Negative symptoms in schizophrenia 46.08 24.26 9 10656 111 64487956
Intentional product misuse 45.66 24.26 58 10607 72237 64415830
Nausea 45.62 24.26 38 10627 785762 63702305
Overdose 44.56 24.26 88 10577 159478 64328589
Bradykinesia 42.33 24.26 21 10644 6539 64481528
Tardive dyskinesia 41.06 24.26 23 10642 9155 64478912
Blood prolactin increased 40.92 24.26 17 10648 3511 64484556
Mental impairment 40.20 24.26 28 10637 16315 64471752
Irritability 39.64 24.26 39 10626 36707 64451360
Sluggishness 39.12 24.26 19 10646 5651 64482416
Confabulation 38.89 24.26 10 10655 449 64487618
Disorientation 38.79 24.26 47 10618 55781 64432286
Intestinal pseudo-obstruction 38.78 24.26 14 10651 1986 64486081
Hyperammonaemic encephalopathy 38.63 24.26 17 10648 4041 64484026
Urinary incontinence 38.31 24.26 38 10627 36113 64451954
Reduced facial expression 38.03 24.26 14 10651 2099 64485968
Postoperative respiratory failure 37.62 24.26 8 10657 154 64487913
Hypothermia 37.49 24.26 29 10636 19827 64468240
Sudden death 37.18 24.26 29 10636 20067 64468000
Eosinophilic myocarditis 37.08 24.26 11 10654 841 64487226
Pain 36.98 24.26 23 10642 553488 63934579
Rabbit syndrome 36.53 24.26 9 10656 339 64487728
Pain in extremity 36.10 24.26 4 10661 303081 64184986
Coma 35.65 24.26 57 10608 87558 64400509
Galactorrhoea 35.62 24.26 15 10650 3204 64484863
Drug monitoring procedure incorrectly performed 35.24 24.26 9 10656 393 64487674
Shock 34.74 24.26 37 10628 38203 64449864
Accommodation disorder 33.02 24.26 9 10656 507 64487560
Asthenia 32.65 24.26 15 10650 428029 64060038
Refusal of treatment by patient 32.23 24.26 19 10646 8320 64479747
Mutism 31.24 24.26 12 10653 2022 64486045
Dysphoria 31.17 24.26 15 10650 4373 64483694
Distractibility 31.02 24.26 9 10656 637 64487430
Drug level increased 30.90 24.26 33 10632 34163 64453904
Hallucination, visual 30.87 24.26 30 10635 27804 64460263
Disorganised speech 29.94 24.26 11 10654 1639 64486428
Leukocytosis 29.92 24.26 34 10631 37706 64450361
Akinesia 29.64 24.26 13 10652 3066 64485001
Electrocardiogram QT prolonged 28.70 24.26 49 10616 79399 64408668
White blood cell count increased 28.30 24.26 44 10621 65970 64422097
Medication error 28.29 24.26 38 10627 49928 64438139
Neutrophil count increased 27.67 24.26 27 10638 25147 64462920
Dyspnoea 27.56 24.26 48 10617 718626 63769441
Cogwheel rigidity 27.31 24.26 12 10653 2841 64485226
Polydipsia 27.17 24.26 15 10650 5806 64482261
Wrong patient received product 27.15 24.26 13 10652 3749 64484318
Drug screen false positive 27.04 24.26 9 10656 1003 64487064
Inappropriate antidiuretic hormone secretion 26.57 24.26 25 10640 22264 64465803
Thinking abnormal 26.57 24.26 19 10646 11537 64476530
Back pain 25.86 24.26 5 10660 250166 64237901
Electrocardiogram J wave 25.80 24.26 5 10660 59 64488008
Water intoxication 25.46 24.26 8 10657 742 64487325
Parkinsonian gait 24.49 24.26 8 10657 841 64487226
Parkinsonism hyperpyrexia syndrome 24.41 24.26 6 10659 224 64487843

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04AA02 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
ANTICHOLINERGIC AGENTS
Tertiary amines
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:50370 parasympatholytics
CHEBI has role CHEBI:66956 antidyskinetic agent
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Postencephalitic parkinsonism indication 19972008 DOID:14332
Parkinsonism indication 32798002
Parkinson's disease indication 49049000 DOID:14330
Extrapyramidal disease indication 76349003
Arteriosclerotic Parkinsonism indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Severe chronic ulcerative colitis contraindication 14311001
Disorder of autonomic nervous system contraindication 15241006
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Shigellosis contraindication 36188001
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Dysuria contraindication 49650001
Paralytic ileus contraindication 55525008 DOID:8442
Ulcerative colitis contraindication 64766004 DOID:8577
Hiatal hernia contraindication 84089009 DOID:12642
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Thyrotoxicosis contraindication 90739004 DOID:7997
Myasthenia gravis contraindication 91637004 DOID:437
Tardive dyskinesia contraindication 102449007
Dysentery contraindication 111939009
Gastrointestinal obstruction contraindication 126765001
Bleeding contraindication 131148009
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Fever contraindication 386661006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Pseudomembranous enterocolitis contraindication 397683000
Gastric ulcer contraindication 397825006 DOID:10808
Disorder of coronary artery contraindication 414024009




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Kd 9.32 IUPHAR CHEMBL
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Kd 8.20 IUPHAR
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Kd 8.41 IUPHAR
Muscarinic acetylcholine receptor M4 GPCR ANTAGONIST Kd 8.62 IUPHAR
Muscarinic acetylcholine receptor M5 GPCR Ki 8.20 PDSP
Neuronal acetylcholine receptor subunit alpha-2 Ion channel WOMBAT-PK

External reference:

IDSource
4019635 VUID
N0000147728 NUI
D00779 KEGG_DRUG
1235-82-1 SECONDARY_CAS_RN
7085-45-2 SECONDARY_CAS_RN
151311 RXNORM
C0005578 UMLSCUI
CHEBI:3112 CHEBI
CHEMBL1101 ChEMBL_ID
CHEMBL1201035 ChEMBL_ID
CHEMBL1201067 ChEMBL_ID
DB00810 DRUGBANK_ID
D001712 MESH_DESCRIPTOR_UI
2381 PUBCHEM_CID
7128 IUPHAR_LIGAND_ID
C036432 MESH_SUPPLEMENTAL_RECORD_UI
915 INN_ID
0FRP6G56LD UNII
4285 MMSL
d00972 MMSL
001644 NDDF
001645 NDDF
001646 NDDF
10020007 SNOMEDCT_US
387359004 SNOMEDCT_US
61742009 SNOMEDCT_US
65041000 SNOMEDCT_US
4018474 VANDF
4018475 VANDF
4019635 VANDF

Pharmaceutical products:

None